EXHIBIT 99.1
Press Release


FOR IMMEDIATE RELEASE
- ---------------------

                  ZONAGEN AUTHORIZES STOCK REPURCHASE PROGRAM

                  Seeks engagement of investment banking firm

THE WOODLANDS, TEXAS - APRIL 2, 2003 - Zonagen, Inc. (Nasdaq: ZONA and PCX:
ZNG) announced today that its Board of Directors has authorized the Company to
repurchase up to $2.5 million of the Company's common stock from time to time
through privately negotiated third party transactions or in the open market.
The Company has approximately 11.5 million shares of common stock currently
outstanding.

The Company also announced today that it is seeking the engagement of an
investment banking firm to review strategic alternatives for redeploying its
assets.

"We authorized our repurchase program to take advantage of prices that we
believe do not reflect the full value of our common stock. We also believe that
reducing the amount of shares we currently have outstanding will provide a
greater value to our remaining shareholders in the event we undertake a
transaction as a result of our proposed engagement of an investment banking
firm," said Martin P. Sutter, Chairman of the Board. "We will continue to seek
the best possible outcome for our stockholders," he concluded.

About Zonagen

Zonagen is engaged in the development of pharmaceutical products for the
reproductive system. For more information, visit Zonagen's web site at
http://www.zonagen.com.

Any statements that are not historical facts contained in this release, such as
Zonagen's contemplated stock repurchases and its potential strategic options,
are forward-looking statements that involve risks and uncertainties, including
but not limited to those risks identified in Zonagen's Annual Report on Form
10-K for the year ended December 31, 2001, as filed with the Securities and
Exchange Commission (SEC). This and other SEC filings are available on request
from Zonagen or at www.sec.gov. Zonagen disclaims any intention or obligation
to update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise.

Contact:
Joe Podolski, President and CEO
podolski@zonagen.com
281-719-3447